2022 Psychotropic New Drug Update

Speaker

Stephen R. Saklad, Pharm.D., BCPP
Director, Psychiatric Pharmacy Program
Clinical Professor
The University of Texas at Austin College of Pharmacy

Learning Objectives

Describe the pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs recently marketed as well as drugs approaching the market.
Review pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs that have been released in the past five years.

Instructions

This program consists of one video and downloadable resources in PDF format.

To begin, scroll to the bottom of this page and click the green "Purchase Now" button. You will then be asked to log in or create an account. If you have taken a course with UT Pharmacy CE previously, be sure to use the same login as before. Once you are logged in, you can complete the registration and then take the course. After you have registered, you will be able to access this course at any time until the expiration date.

Speaker information and disclosures can be found in the tab below.

Fee

$20.00

CE Hours

1.00

CE Units

0.100

Activity Type

Knowledge

Support/Credits

Continuing Education Credit

The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This online activity is approved for 0.10 CEUs (1.00 contact hour) of continuing education credit. To receive 1.00 contact hour of CE credit, the participant must watch the included video in its entirety, pass the online post-test ( >70% within 5 attempts), and complete the online evaluation. Upon successfully completing the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3-7 days).

2022 Psychotropic New Drug Update

About the Speaker

Stephen R. Saklad, Pharm.D., BCPP
Director, Psychiatric Pharmacy Program
Clinical Professor
The University of Texas at Austin College of Pharmacy

Dr. Saklad is a Clinical Professor at The University of Texas College of Pharmacy and a Pharmacist at San Antonio State Hospital since 1979. He has focused his career on clinical care, teaching, and research to improve the quality of life and function in the serious and persistently mentally ill. He helped to create a clinical research unit at San Antonio State Hospital and developed the first websites for The University of Texas College of Pharmacy and the College of Psychiatric and Neurologic Pharmacists (CPNP). He is the Director of the University of Texas Psychiatric Pharmacy Program in San Antonio, having trained over 70 advanced practice pharmacists in psychiatric pharmacy. Dr. Saklad is a Founding Member of CPNP, served on the CPNP Board of Directors and was the founding senior editor of their peer-reviewed journal, the Mental Health Clinician. He has published articles and presented to many groups around the country on a variety of pharmacy and mental health-related topics. He is a principal or co-investigator for several studies of the efficacy and adverse effects of Phase II, III, and IV psychotropic agents in schizophrenia, mood disorders, and other serious mental illnesses, as well as their pharmacokinetics and interactions. He has received several honors, most recently the Judith J. Saklad Memorial Award from CPNP in 2012 and the Teaching Excellence Award from the UT College of Pharmacy in 2013.

Disclosure: Dr. Saklad has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

Employee of Texas Department of Health Services San Antonio

Speakers Bureau: Actavis, Otsuka, Sunovion

Consultant: Janssen, Jazz, Otsuka, Teva

Other: Member of Pharmacists Foundation, Business Development Council for San Antonio

Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.

Activity Number

0067-0000-22-122-H01-P

Release Date: Oct 13, 2022

Credit Expiration Date: Oct 12, 2025

CE Hours

1.00